Rezolute (RZLT) Capital Leases (2014 - 2015)
Rezolute recorded quarterly Capital Leases of $23127.0 in Q2 2015, down 50.74% quarter-over-quarter from $46946.0 in Q1 2015.
Rezolute's Capital Leases history runs 2 years deep, the most recent figure standing at $23127.0 for Q2 2015.
- In Q2 2015, Capital Leases changed N/A year-over-year to $23127.0; the TTM figure through Jun 2015 stood at $23127.0 (changed N/A YoY), while the FY2015 annual figure was $23127.0, changed N/A from the prior year.
- Capital Leases came in at $23127.0 for Q2 2015 at Rezolute, down from $46946.0 in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $70677.0 in Q4 2014 to a low of $8075.0 in Q3 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 23,127.00 |
| Mar 31, 2015 | 46,946.00 |
| Dec 31, 2014 | 70,677.00 |
| Sep 30, 2014 | 8,075.00 |